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Background: Kampo medicines are traditional Japanese medicines produced from medicinal plants and herbs.
Even though the efficacy of Kampo medicines for controlling cancer-related symptoms is being reported, their
actual nationwide clinical use has not been comprehensively investigated. We aimed to investigate physicians’
recognition of Kampo medicines and their clinical use for cancer patients in the field of palliative care.
Methods: A cross-sectional self-administered anonymous questionnaire was distributed to 549 physicians working
in palliative care teams at 388 core cancer treatment hospitals and 161 certified medical institutions that have
palliative care units (PCUs).
Results: Valid responses were obtained from 311 physicians (response rate, 56.7%) who were evenly distributed
throughout the country without significant geographical biases. Kampo medicines were prescribed for controlling
cancer-related symptoms by 64.3% of the physicians. The symptoms treated with Kampo medicines were
numbness/hypoesthesia (n = 99, 49.5%), constipation (n = 76, 38.0%), anorexia/weight loss (n = 72, 36%), muscle
cramps (n = 71, 35.5%) and languor/fatigue (n = 64, 32.0%). Regarding open issues about prescription, 60.7%
(n = 173) of the physicians raised the issue that the dosage forms need to be better devised.
Conclusions: To increase the clinical use of Kampo medicines, more evidence from clinical studies is necessary. In
addition, their mechanisms of action should be clarified through laboratory studies.
Keywords: Kampo, Kampo medicine, Palliative care, Symptom management, SurveyBackground
History of kampo medicine
Kampo medicines are traditional Japanese medicines
produced from medicinal plants and herbs. Kampo origi-
nates from China and has been adapted to the Japanese
culture [1]. Chinese herbal medicine was imported to
Japan in 552 AD, after which it was uniquely developed
into Japanese Kampo [2]. Traditional Chinese Medicine
is deeply philosophical and ideological, while Japanese
Kampo tends to be more practical and simplified, and
relies little on Taoist or other Chinese philosophy [2].* Correspondence: tempeimiyaji@iii.u-tokyo.ac.jp
3Interfaculty Initiative in Information Studies, The University of Tokyo, 7-3-1
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reproduction in any medium, provided the orKampo medicines are currently of great interest to pal-
liative care physicians because of their potential to allevi-
ate the adverse side effects of cancer treatment and
improve patients’ quality of life.
Use of Kampo and CAM in Japan
In the past few decades, Kampo has reintegrated into
modern medical practice, accompanied by a scientific
reevaluation and critical examination of its relevance in
conventional medicine [2,3]. Kampo has been used in
addition or alternatively to conventional medicines [4].
Currently more than 70% of Japanese physicians pre-
scribe Kampo medicines in daily clinical practices [5].
Previous survey research has reported that 76% of the
general population in Japan and 50% of outpatients intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the general population and 19% of outpatients in Tokyo
had used Kampo medicine prescribed by physicians
within the last 12 months [6,7]. In addition, the preva-
lence of use of CAM by cancer patients was 44.6% in
Japan [8]. Internationally, the estimates of CAM use are
higher in East Asia and highest in Japan compared to
the USA and European countries [9,10]. CAM is often
used in palliative care settings where the goal is not cure
but rather improvement in QOL [10].
To date, the Ministry of Health, Labour and Welfare
(MHLW) has approved the use of 148 Kampo medi-
cines, and the prescription of Kampo medicines is within
the national health insurance system [3,11]. Although
Kampo can be seen as orthodox from a historical Japanese
perspective, it tends to be classified as Complementary
and Alternative Medicine (CAM) according to Western
conventions. The main reason for this is the lack of sci-
entific evidence of its efficacy and the limited knowledge
and spread of this therapy in other regions, especially
outside of East Asia.
However, clinical studies of Kampo have been con-
ducted in Japan, and its efficacy has been reported in re-
search papers. For example, a randomized control trial
demonstrated that the Kampo medicine Rikkunshito ex-
erted greater effects in alleviating gastrointestinal symp-
toms than cisapride (a gastroprokinetic agent) [12]. The
efficacy of Rikkunshito against non-ulcer dyspepsia (NUD)
[13,14], gastrointestinal symptoms after gastrectomy (sur-
gical NUD) [15], functional dyspepsia [16,17], and nausea
and vomiting caused by selective serotonin reuptake
inhibitors [18] has also been reported. Also, the Japanese
Society for Oriental Medicine has compiled comprehen-
sive data on randomized controlled trials of Kampo
medicine in Japan, published as “Evidence Reports of
Kampo Treatment” (EKAT) [19]. In addition to clinical
trials, the potential mechanisms of action of Kampo
medicines are also starting to be reported [20].
As described above, there is increasing evidence of the
efficacy of Kampo medicines and increasing attention
has been given to their clinical application. However,
there has been no comprehensive investigation of the
use of Kampo medicines in cancer treatment. Therefore,
we conducted a nationwide survey of the current use of
Kampo medicines for cancer-related treatment and of
physicians’ attitudes toward using Kampo medicines in
Japan.
Methods
Study sample and data collection
The survey was carried out between January and March
of 2011, by mailing a self-administered anonymous ques-
tionnaire to 549 palliative care physicians who adminis-
ter chemotherapy to cancer patients or who are involvedin their terminal care. The palliative care teams in 388
core cancer treatment hospitals and 161 palliative care
units (PCUs) within medical institutions were selected
because they represent palliative care practice in Japan.
This included all core cancer treatment hospitals and
PCUs in Japan as of February 2011. Core cancer treat-
ment hospitals are the medical facilities specified by the
MHLW to provide high-quality expert care for cancer
patients. These facilities are established within each pre-
fecture in Japan, according to the principles set forth in
the Cancer Control Act promulgated in April 2007. The
contact information of subjects was obtained from a web
site of the Cancer Control Information Center, National
Cancer Center [21].
We did not specifically include general internists or
surgeons who are not in charge of palliative care as sub-
jects of the survey. This is because the certification sys-
tem for the palliative care specialist is still immature in
Japan and the attending physicians of palliative care
teams and PCUs are often internists or surgeons.Questionnaire development
An eight-page, 18-item questionnaire was designed in
Japanese. It covered four categories: (1) status of cancer
treatment and use of Kampo medicines, (2) cancer cach-
exia and utilization of Kampo medicines (data not
shown), (3) adverse side effects of anti-cancer drugs and
utilization of Kampo medicines, and (4) background
variables. Although the questionnaire was not formally
validated, the questionnaire and its items were designed
and formulated based upon the expert opinions of spe-
cialists from palliative care, medical oncology, Kampo
medicine, and biological statistics, and also from literature
reviews. It was finalized after testing several samples.Ethical considerations
We conducted this research in compliance with the
Helsinki Declaration. We had requested an ethical re-
view of this research from the ethical review committee
of the National Cancer Center prior to commencement.
However, since this research involves neither patients’
data nor intervention, the committee judged that this re-
search should not be subjected to any Japanese medical
research guidelines. Accordingly, the research was ex-
empt from the requirement for formal ethical approval.
To ensure that informed consent was obtained, the
questionnaire was sent to the physicians with a leaflet
explaining the survey’s objectives and that (1) each sub-
ject was free to decide whether or not to answer the
questions; (2) the collected data will be processed and
analyzed anonymously; and (3) the data will be securely
archived by the Research Secretariat. Consent was im-
plied through the return of a completed questionnaire.
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The collected data were entered into an electronic
database and analyzed using SPSS (IBM, New York,
USA). Chi-squared tests (p value < 0.050) were con-
ducted to compare the frequency distributions of two
cross-tabulations. The first was physicians in the pallia-
tive care teams at the core cancer treatment hospitals
compared with physicians in the PCUs. The second
was the palliative care specialists certified by the Japan
Society of Palliative Medicine (JSPM) compared with
non-specialists.Results and discussion
Of the 549 questionnaires distributed, 311 valid responses
were collected for analysis (response rate, 56.7%). Re-
sponses were obtained from 226 physicians (response
rate, 58.2%) at core cancer treatment hospitals (palliative
care team physicians) and 79 physicians (response rate,
49.1%) from PCUs (PCU physicians). With the moderate
rate of valid responses (56.7%), the respondents were
well-distributed throughout the country, without sig-
nificant geographical biases. Table 1 shows the responseTable 1 Respondents’ background characteristics
Respondents (n = 311)
Age
Years of experience
Institution (n = 549) *
Core cancer treatment hospital (n = 388)










Palliative Care Specialists certified by JSPM**
Specialists (including provisional medical advisors)
Non-specialists
Region*** Hokkaido–Tohoku Kanto
Number of questionnaires distributed 79 116
Number of responses 26 43
Response rate (%) 32.9 37.1
*Six responses had missing institution data, and ***95 responses had missing regio
** JSPM: Japan Society for Palliative Medicine.rates and the respondents’ background characteristics.
Two hundred thirty seven respondents (77.9%) were aged
between 40 and 59 years. Two hundred seventy three
respondents (90.1%) were male, and 128 respondents
(41.2%) were JSPM-authorized palliative care specialists
(including provisional medical advisors).Difficult to treat cancer-related symptoms
Physicians were asked to identify which of the 23 common
cancer-related symptoms that they find difficult to treat
(Table 2). More than 50% of the physicians identified
numbness/hypoesthesia (n = 240, 77.2%), languor/fatigue
(n = 225, 72.3%), delirium (N = 170, 54.7%), and taste al-
teration (n = 166, 53.4%). In comparison with the PCU
physicians, more palliative care team physicians identi-
fied taste alteration (p = 0.029), nausea/vomiting (during
chemotherapy) (p = 0.000), and constipation (caused by
opioid use) (p = 0.038). More of the PCU physicians, on
the other hand, reported having difficulty treating adjust-
ment disorder (p = 0.014). In addition, the symptoms of
taste alteration (p = 0.050), dysphagia/deglutition dis-
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Chubu Kinki Chugoku Shikoku Kyushu–Okinawa
92 91 47 27 97
41 33 25 11 37
44.6 36.3 53.2 40.7 38.1
n data.












frequency % frequency % frequency % frequency % frequency %
Numbness/Hypesthesia 240 77.2 180 79.6 55 69.6 0.165 99 77.3 141 77.0 1.000
Languor/Fatigue 225 72.3 161 71.2 61 77.2 0.276 99 77.3 126 68.9 0.122
Delirium 170 54.7 119 52.7 48 60.8 0.447 73 57.0 97 53.0 0.490
Taste alteration 166 53.4 124 54.9 42 53.2 0.029 77 60.2 89 48.6 0.050
Edema (Local edema/Anasarca) 150 48.2 109 48.2 39 49.4 0.821 59 46.1 91 49.7 0.565
Pain 146 46.9 113 50.0 31 39.2 0.226 55 43.0 91 49.7 0.250
Anorexia/Weight loss 140 45.0 109 48.2 30 38.0 0.108 64 50.0 76 41.5 0.165
Abdominal discomfort 131 42.1 98 43.4 31 39.2 0.735 55 43.0 76 41.5 0.816
Stomatitis/Xerostomia 122 39.2 89 39.4 33 41.8 0.141 54 42.2 68 37.2 0.409
Depression 116 37.3 86 38.1 30 38.0 0.175 41 32.0 75 41.0 0.122
Adjustment disorder 113 36.3 73 32.3 39 49.4 0.014 47 36.7 66 36.1 1.000
Dyspnea/Breathlessness 113 36.3 77 34.1 35 44.3 0.162 48 37.5 65 35.5 0.811
Nausea/Vomiting (other) 101 32.5 75 33.2 24 30.4 0.893 38 29.7 63 34.4 0.392
Dysphagia/Deglutition disorder 100 32.2 68 30.1 31 39.2 0.281 50 39.1 50 27.3 0.036
Sleep disorder/Insomnia 93 29.9 69 30.5 23 29.1 0.796 42 32.8 51 27.9 0.379
Constipation (caused by opioid use) 84 27.0 69 30.5 15 19.0 0.038 34 26.6 50 27.3 0.898
Nausea/Vomiting
(during chemotherapy)
76 24.4 71 31.4 5 6.3 0.000 27 21.1 49 26.8 0.284
Muscle weakness 65 20.9 46 20.4 19 24.1 0.346 34 26.6 31 16.9 0.047
Nausea/Vomiting
(caused by opioid use)
61 19.6 51 22.6 10 12.7 0.690 24 18.8 37 20.2 0.774
Constipation
(not caused by opioid use)
59 19.0 47 20.8 11 13.9 0.377 28 21.9 31 16.9 0.305
Muscle cramp 42 13.5 31 13.7 11 13.9 0.741 23 18.0 19 10.4 0.064
Diarrhea 40 12.9 34 15.0 6 7.6 0.136 16 12.5 24 13.1 1.000
Anemia 29 9.3 24 10.6 5 6.3 0.344 16 12.5 13 7.1 0.177
Others 11 3.5 6 2.7 5 6.3 0.325 4 3.1 7 3.8 0.770
Multiple answers allowed, p-value based on Chi-square test.
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liative care specialists than the non-specialists.
Numbness is a neuropathic symptom that frequently
occurs as an adverse side effect of chemotherapy. It has
been reported to account for 58% of all neurological symp-
toms experienced by cancer patients [22]. Fatigue is the
most common cancer symptom [23], and was reported by
66% of patients in a previous study [22]. The prevalence of
delirium is 25–40% (85–88% in the terminal stage of can-
cer) [24-26], and the prevalence of taste alteration is
36–75% among patients receiving chemotherapy [27].
Thus, it was shown in the present survey that the symp-
toms palliative care physicians have difficulty managing in
Japan are those frequently seen in cancer patients.
We also found that the palliative care team physicians
confront taste alteration (p = 0.029), nausea/vomiting dur-
ing chemotherapy (p = 0.000) and constipation during opioid
use (0.038) more often than the PCU physicians (Table 2).
These facts suggest that the palliative care teams are oftenin charge of patients receiving chemotherapy, while PCUs
are more frequently dealing with psychiatric symptoms
than the adverse side effects of chemotherapy.
Prescription of Kampo medicines
Kampo medicines were being prescribed by 64.3% (n = 200)
of the physicians to alleviate the cancer patients’ symptoms.
Kampo medicines were prescribed to control numbness/
hypoesthesia (n = 99, 49.5%), constipation (not caused by
opioid use) (n = 76, 38%), anorexia/weight loss (n = 72, 36%),
muscle cramps (n = 71, 35.5%), and languor/fatigue (n = 64,
32%) by more than 30% of the physicians (Table 3). The
palliative care team physicians prescribed Kampo medicines
for numbness/hypoesthesia (p = 0.000), anorexia/weight loss
(p = 0.046), pain (p = 0.020), and nausea/vomiting during
chemotherapy (p = 0.016), more frequently than the PCU
physicians. This difference may arise because the palliative
care teams more often examine patients who are under
chemotherapy than the PCUs, and thus they pay more








frequency % frequency % frequency %
Numbness/Hypesthesia 99 49.5 86 57.7 12 26.1 0.000
Constipation (not caused by opioid use) 76 38 56 37.6 20 43.5 0.182
Anorexia/Weight loss 72 36 60 40.3 12 26.1 0.046
Muscle cramp 71 35.5 54 36.2 17 37.0 0.279
Languor/Fatigue 64 32 49 32.9 14 30.4 0.818
Constipation (caused by opioid use) 48 24 37 24.8 11 23.9 0.490
Abdominal discomfort 46 23 29 19.5 16 34.8 0.088
Diarrhea 45 22.5 39 26.2 5 10.9 0.090
Delirium 40 20 27 18.1 13 28.3 0.155
Pain 38 19 35 23.5 3 6.5 0.020
Edema (Local edema/Anasarca) 31 15.5 25 16.8 6 13.0 0.546
Nausea/Vomiting (other) 27 13.5 22 14.8 5 10.9 0.566
Nausea/Vomiting (during chemotherapy) 22 11 22 14.8 0 0.0 0.016
Stomatitis/Xerostomia 21 10.5 19 12.8 2 4.3 0.216
Taste alteration 20 10 17 11.4 3 6.5 0.409
Depression 20 10 17 11.4 3 6.5 0.409
Nausea/Vomiting (caused by opioid use) 17 8.5 16 10.7 1 2.2 0.129
Adjustment disorder 15 7.5 12 8.1 3 6.5 0.846
Sleep disorder/Insomnia 14 7 10 6.7 4 8.7 0.823
Others 13 6.5 6 4.0 6 13.0 0.055
Anemia 11 5.5 9 6.0 2 4.3 0.805
Dysphagia/Deglutition disorder 10 5 9 6.0 1 2.2 0.581
Dyspnea/Breathlessness 6 3 5 3.4 1 2.2 1.000
Muscle weakness 3 1.5 3 2.0 0 0.0 0.614
Multiple answers allowed, p-value based on Chai-square test.
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adverse side effects of chemotherapy. Also, PCU patients
have more difficulty taking Kampo medicines than the gen-
eral hospital patients under the palliative care teams. The
frequency of prescribing Kampo medicines did not vary sig-
nificantly across the symptoms between the palliative care
specialists and non-specialists.
Reasons for prescription
More than 60% of the physicians prescribed Kampo med-
icines for the following reasons: ‘the drug therapy options
are greater’ (n = 144, 72%), ‘ineffectiveness of other treat-
ments’ (n = 129, 64.5%), and ‘unavailability of other ap-
propriate treatments’ (n = 127, 63.5%). Although ‘patient
demand’ was the least frequent reason (n = 46, 23%), pal-
liative care specialists were more attentive to patients’
demands than non-specialists (n = 28, 37.3%, p = 0.000).
Variety and frequency of prescriptions
Eight Kampo medicines were selected from the literature
reviews to investigate frequency of prescription. Table 4
shows the composition of each Kampo medicine [28-30].Daikenchuto was the most frequently prescribed (n = 140,
70%) among eight major Kampo medicines (Table 5).
This is probably because the efficacy of Daikenchuto for
the treatment of gastrointestinal symptoms is currently
being tested in clinical trials in Japan and the United
States. A tolerability and efficacy phase II study of
Daikenchuto for the treatment of postoperative ileus has
been already completed in the United States [31]. This
might encourage its prescription by physicians. The
palliative care team physicans prescribed Goshajinkigan
(p = 0.000), Rikkunshito (p = 0.001), Hochuekkito (p = 0.011),
Juzentaihoto (p = 0.001), and Hangeshashinto (p = 0.000)
more frequently than PCU physicians, while there were no
significant differences in themedicines prescribed between
thepalliativecarespecialistsandnon-specialists.
Physician-recognized effectiveness
We investigated the physician-recognized effectiveness of
eight Kampo medicines. Two symptoms from each Kampo
medicine’s package insert were listed and the physicians
were asked to indicate whether they believed the medicine
effectively treated them (Table 6). More than 50% of the
Table 4 Composition of Kampo medicines
Kampo Medicine Ingredients (crude drugs)



























































































Ingredients of each Kampo medicine were based on the package inserts of Tsumura products [28].

























Table 5 The Kampo medicines prescribed by the physicians







frequency % frequency % frequency %
Daikenchuto 140 70.0 109 73.2 29 63.0 0.124
Goshajinkigan 100 50.0 89 59.7 11 23.9 0.000
Rikkunshito 97 48.5 82 55.0 15 32.6 0.001
Shakuyakukanzoto 96 48.0 76 51.0 20 43.5 0.069
Hochuekkito 90 45.0 76 51.0 13 28.3 0.011
Juzentaihoto 84 42.0 73 49.0 11 23.9 0.001
Yokukansan 61 30.5 45 30.2 16 34.8 0.253
Hangeshashinto 54 27.0 51 34.2 3 6.5 0.000
Others 24 12.0 20 13.4 4 8.7 0.457
Multiple answers allowed, p-value based on Chi-square test.
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against diarrhea caused by chemotherapy (n = 31, 53.4%), of
Hochuekkito and Juzentaihoto against fatigue (n = 54, 56.3%
and n = 50, 56.8% respectively), of Rikkunshito against
anorexia (n = 46, 50%), of Yokukansan against delirium
(n = 38, 63.3%), of Shakuyakukanzoto against leg cramps
(n = 79, 82.3%), and of Daikenchuto against ileus (n = 101,
78.9%) and opioid-caused constipation and abdominal pain
(n = 62, 53.9%). There was no significant difference in the
medicines recognized as effective between the palliative care
team and PCU physicians, while the palliative care specia-
lists seemed to be more aware of the effectiveness of






















Goshajinkigan Numbness of hands and feet 47/107
Nocturia 13/60
Multiple answers allowed, p-value based on Chi-square test.(Table 6). These results suggest that there is consensus
among palliative care physicians regarding the effectiveness
of particular Kampo medicines against particular symptoms.
Prescription considerations
In the questionnaire, the physicians were asked, “What
are the important considerations when selecting a
Kampo medicine for prescription?”. More than 80% of
the physicians recognized the importance of ‘symptom-
alleviating effects (alleviation of adverse side effects)
(n = 173, 93%)’, ‘alleviation of symptoms that reduce QOL
in the terminal stage of cancer’ (n = 162, 87.6%), ‘low inci-
dence of adverse side effects’ (n = 157, 84.9%) and ‘easyes
Recognized as effective
ns Specialists Non-specialists p-value
% frequency/total % frequency/total %
53.4 10/22 45.5 21/36 58.3 0.420
22.2 3/21 14.3 7/24 29.2 0.296
48.9 14/36 38.9 30/54 55.6 0.137
56.3 19/39 48.7 35/57 61.4 0.295
43.9 9/34 26.5 27/48 56.3 0.012
50.0 18/40 45.0 28/52 53.8 0.528
56.8 17/33 51.5 33/55 60.0 0.508
46.6 7/22 31.8 20/36 55.6 0.106
63.3 18/26 69.2 20/34 58.8 0.433
30.0 6/23 26.1 9/27 33.3 0.758
82.3 36/43 83.7 43/53 81.1 0.794
35.1 11/25 44.0 9/32 28.1 0.268
78.9 35/48 72.9 66/80 82.5 0.263
53.9 22/47 46.8 40/68 58.8 0.254
43.9 18/39 46.2 29/68 42.6 0.840
21.7 4/26 15.4 9/34 26.5 0.358
Table 7 Open issues about prescribing Kampo medicine (n = 285)
Issue frequency %
The dose and dosage forms need to be better devised for simpler application 173 60.7
No evidence of efficacy from placebo-controlled studies 109 38.2
Action mechanism of Kampo medicine is not yet elucidated 97 34.0
No opportunity to learn about Kampo medicines 90 31.6
Relatively weak effect 79 27.7
Drug interaction is uncertain 66 23.2
Production of effect is slow 56 19.6
Others 25 8.8
There are no issues 12 4.2
Multiple answers allowed.
Iwase et al. BMC Complementary and Alternative Medicine 2012, 12:222 Page 8 of 9
http://www.biomedcentral.com/1472-6882/12/222to combine with other drugs’ (n = 149, 80.5%). The pallia-
tive care specialists tended to place more importance than
the non-specialists on ‘patient demand’ (p = 0.050).Open issues for prescription
The questionnaire also asked the physicians to identify
any open issues regarding the prescription of Kampo
medicines (Table 7), revealing that 60.7% (n = 173) of the
physicians were concerned that the dose and dosage
forms need to be better devised for simpler administra-
tion. Kampo medicines are commonly prepared in gran-
ule form or as decoctions, and their administration
method is nauseating for some patients. This issue may
be related to the observation that “patient demand” was
chosen least frequently as the reason for prescription. In
the clinical field of palliative care, Kampo medicines are
often mixed in a jelly for patients who have dysphagia.
For future prescriptions, the administration forms need
to be better devised from an adherence perspective. The
second most frequently identified issue was the lack of
scientific evidence for their efficacy, with 38.2% (n = 109)
of the physicians highlighting the absence of evidence
from placebo-controlled trails. Watanabe et al. [3] re-
cently reported a summary of 135 peer-reviewed Kampo
trials published between 1988 and 2007. According to
their report, 106 trials were RCTs, and only 22 were
placebo-controlled trials. In two-thirds of the trials, the
sample size was less than 100 patients, and only 35 trials
were published in English and the rest were in Japanese.
Watanabe et al. [3] concluded that the overall quality of
the research was low.Conclusions
We conducted a nationwide survey of 311 physicians
working in palliative care teams at core cancer treatment
hospitals and PCUs within medical facilities. Kampo
medicines were prescribed by a high proportion (n = 200,
64.3%) of the palliative care physicians and were expected
to provide valid means of controlling the cancer patients’symptoms or the adverse side effects of chemotherapy.
Palliative care physicians appear to be aware of the effect-
iveness of Kampo medicines. However, they prescribe
Kampo medicines only to a limited extent because of the
lack of evidence for their efficacy. Hence, we believe that
the collection of more evidence from clinical studies is
desirable in Japan.
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